The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine

Vaccine

Volumn 31, Issue 36, 2013, Pages 3712-3717

  Cameron, Michael P ^a   Newman, Peter A ^b   Roungprakhon, Surachet ^c   Scarpa, Riccardo ^a,d  

^a UNIVERSITY OF WAIKATO   (New Zealand)

^b UNIVERSITY OF TORONTO   (Canada)

^c RAJAMANGALA UNIVERSITY OF TECHNOLOGY PHRA NAKHON   (Thailand)

^d UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Conjoint analysis; Discrete choice; HIV vaccine; Thailand; Willingness to pay

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG EFFICACY; EXTERNAL VALIDITY; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PAIN; PATIENT ATTITUDE; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; RASH; STRUCTURED QUESTIONNAIRE; TASK PERFORMANCE; THAILAND; TREATMENT DURATION; VACCINATION; WILLINGNESS TO PAY;

CONJOINT ANALYSIS; DISCRETE CHOICE; HIV VACCINE; THAILAND; WILLINGNESS-TO-PAY;

ADULT; AIDS VACCINES; CHOICE BEHAVIOR; FEES AND CHARGES; FEMALE; HIV INFECTIONS; HUMANS; LIKELIHOOD FUNCTIONS; LOGISTIC MODELS; MALE; PATIENT PARTICIPATION; QUESTIONNAIRES; THAILAND;

EID: 84880933797     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.089     Document Type: Article

References (63)

1. Fauci A.S., Johnston M.I., Dieffenbach C.W., Burton D.R., Hammer S.M., Hoxie J.A., et al. HIV vaccine research: the way forward. Science 2008, 321:530-532.
2. Haynes B.F., Liao H., Tomaras G.D. Is developing an HIV-1 vaccine possible?. Curr Opin HIV AIDS 2010, 5:362-367.
3. Kim J.H., Rerks-Ngarm S., Excler J., Michael N.L. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010, 5:428-434.
4. UNAIDS Report on the global AIDS epidemic 2012 2012, UNAIDS, Geneva.
5. Youle M., Wainberg M.A. Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine?. AIDS 2003, 17:937-938.
6. Granich R., Gupta S., Suthar A., Smyth C., Hoos D., Vitoria M., et al. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 2011, 9:446-469.
7. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
8. Voronin Y., Manrique A., Bernstein A. The future of HIV vaccine research and the role of the global HIV vaccine enterprise. Curr Opin HIV AIDS 2010, 5:414-420.
9. Bonner S. Implementation science and urban health research. J Urban Health 2009, 86:157-160.
10. Weinberg G.A., Szilagyi P.G. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis 2010, 20:1607-1610.
11. Newman P.A., Duan N., Rudy E.T., Anton P.A. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come?. AIDS Patient Care STDs 2004, 18:691-701.
12. Newman P.A., Logie C. HIV vaccine acceptability: a systematic review and meta-analysis. AIDS 2010, 24:1749-1756.
13. Newman P.A., Duan N., Kakinami L., Roberts K. What can HIV vaccine trials teach us about dissemination?. Vaccine 2008, 26:2528-2536.
14. Newman P.A., Logie C., James L., Charles R., Maxwell J., Salam K., et al. "Speaking the dialect": understanding public discourse in the aftermath of an HIV vaccine trial shutdown. Am J Pub Health 2011, 101:1749-1758.
15. Newman P.A. Eight common misconceptions about HIV vaccines that may impede progress in controlling the AIDS epidemic. Future Virol 2012, 7:737-740.
16. Hom D.L., Johnson J.L., Mugyeni P. HIV-1 risk and vaccine acceptability in the Ugandan military. J Acquir Immun Defic Syndr 1997, 15:375-380.
17. Lally M., Gaitania M., Vallabhanemi S., Reinert S., Mayer K., Zimet G., et al. Willingness to receive an HIV vaccine among incarcerated persons. Prev Med 2006, 43:402-405.
18. Crosby R.A., Holtgrave D.R., Bryant L., Frew P.M. Correlates of negative intent to receive an AIDS vaccine: an exploratory study. Int J STD AIDS 2004, 15:552-557.
19. Newman P.A., Lee S.J., Duan N., Rudy E., Nakazono T.K., Boscardin J., et al. Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES). Health Serv Res 2009, 44:2167-2179.
20. Liau A., Zimet G.D., Fortenberry J.D. Attitudes about Human Immunodeficiency Virus immunization. Sex Transm Dis 1998, 25:76-81.
21. Mays R.M., Zimet G.D. Recommending STI vaccination to parents of adolescents: the attitudes of nurse practitioners. Sex Transm Dis 2004, 31:428-432.
22. Bishai D., Pariyo G., Ainsworth M., Hill K. Determinants of personal demand for an AIDS vaccine in Uganda: a contingent valuation survey. Bull World Health Organ 2004, 82:652-660.
23. Suraratdecha C., Ainsworth M., Tangcharoensathien V., Whittington D. The private demand for an AIDS vaccine in Thailand. Health Policy 2005, 71:271-287.
24. Cameron M.P., Lim S., Scarpa R., Tressler J., Wu F., Zhou Y. The private demand for an HIV vaccine in China (abstract TuPA121). 9th International Conference on AIDS in Asia and the Pacific 2009.
25. Mitchell R., Carson R. Using surveys to value public goods: the contingent valuation method 1989, Resources for the Future, Washington, D.C.
26. Hecht R., Suraratdecha C. Estimating the demand for a preventive HIV vaccine: why we need to do better. PLoS Med 2006, 3:1728-1732.
27. Zimet G.D., Fortenberry J.D., Blythe M.J. Adolescents' attitudes about HIV immunization. J Pediatr Psychol 1999, 24:67-75.
28. Zimet G.D., Blythe M.J., Fortenberry J.D. Vaccine characteristics and acceptability of HIV immunization among adolescents. Int J STD AIDS 2000, 11:143-149.
29. Sapéde C., Girod I. Willingness of adults in Europe to pay for a new vaccine: the application of discrete choice-based conjoint analysis. Int J Market Res 2002, 44:463-476.
30. Newman P.A., Duan N., Lee S.J., Rudy E.T., Seiden D.S., Kakinami L., et al. HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Vaccine 2006, 24:2094-2101.
31. Kakinami L., Newman P.A., Lee S.J., Duan N. Differences in HIV vaccine acceptability between genders. AIDS Care 2008, 20:542-546.
32. Zimet G.D., Perkins S.M., Sturm L.A., Bair R.M., Juliar B.E., Mays R.M. Predictors of STI vaccine acceptability among parents and their adolescent children. J Adolesc Health 2005, 37:179-186.
33. Bridges J.F.P., Kinter E.T., Kidane L., Heinzen R.R., McCormick C. Things are looking up since we starting listening to patients - trends in the application of conjoint analysis in health 1982-2007. Patient 2008, 1:273-282.
34. McFadden D. Conditional logit analysis of qualitative choice behavior. Frontiers in Econometrics 1973, Academic Press, New York. P. Zarembka (Ed.).
35. McFadden D. Computing willingness to pay in random utility models. Trade - theory and econometrics 1999, Routledge, London. J. Moore, R. Reizman, J. Melvin (Eds.).
36. McConnell K.E. Consumer surplus from discrete choice models. J Environ Econ Manage 1995, 29:263-270.
37. Hausman J., Ruud P. Specifying and testing econometric models for rank-ordered data. J Econometrics 1987, 34:83-103.
38. Caparros A., Oviedo J.L., Campos P. Would you choose your preferred option? Comparing choice and recoded ranking experiments. Am J Agric Resour Econ 2008, 90:843-855.
39. McFadden D. Econometric models for probabilistic choice among products. J Bus 1980, 53:S13-S29.
40. Structural analysis of discrete data with econometric applications 1981, MIT Press, Cambridge, MA. C.F. Manski, D. McFadden (Eds.).
41. Train K. Discrete choice methods with simulation 2003, Cambridge University Press, Cambridge.
42. Newman P.A., Roungprakhon S., Tepjan S., Yim S., Walisser R. A social vaccine? Social and structural contexts of HIV vaccine acceptability among high-risk populations in Thailand. Global Public Health 2012, 7:1009-1024.
43. Plackett R.L., Burman J.P. The design of optimum multifactorial experiments. Biometrika 1946, 33:305-325.
44. Ratcliffe J. The use of conjoint analysis to elicit willingness-to-pay values - proceed with caution?. Int J Technol Assess Health Care 2000, 16:270-290.
45. Hauber A.B. Issues that may affect the validity and reliability of willingness-to-pay estimates in stated-preference studies. Patient 2008, 1:249-250.
46. Frankel M.R., Shapiro M.F., Duan N., Morton S.C., Berry S.H., Brown J.A., et al. National probability samples in studies of low-prevalence diseases. Part II. Designing and implementing the HIV cost and services utilization study sample. Health Serv Res 1999, 34:969-992.
47. van Griensven F., Varangrat A., Wimonsate W., Tanpradech S., Kladsawad K., Chemnasiri T., et al. Trends in HIV prevalence, estimated HIV incidence and risk behavior among men who have sex with men in Bangkok, Thailand, 2003-2007. J AIDS 2010, 53:234-239.
48. Newman P.A., Lee S.J., Roungprakhon S., Tepjan S. Demographic and behavioral correlates of HIV risk among men and transgender women recruited from gay entertainment venues and community-based organizations in Thailand: implications for HIV prevention. Prev Sci 2012, 13:483-492.
49. Baker R.P. New technology in survey research: computer-assisted personal interviewing (CAPI). Soc Sci Comp Rev 1992, 10:145-157.
50. Newman P.A., Roungprakhon S., Tepjan S., Yim S. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine 2010, 28:958-964.
51. Ryan M. Deriving welfare measures in discrete choice experiments: a comment to Lancsar and Savabe (I). Health Econ 2004, 13:909-912.
52. Marley A., Louviere J. Some probabilistic models of best, worst, and best-worst choices. J Math Psychol 2005, 49:464-480.
53. Louviere J.J., Islam T. A comparison of importance weights and willingness-to-pay measures derived from choice-based conjoint, constant sum scales and best-worst scaling. J Bus Res 2008, 61:903-911.
54. Haab T.C., McConnell K.E. Valuing environmental natural resources: the econometrics of non-market valuation 2002, Edward Elgar Publishing, Northampton, MA.
55. Liau A., Zimet G.D. The acceptability of HIV immunization: examining vaccine characteristics as determining factors. AIDS Care 2001, 13:643-650.
56. Heal G., Kunreuther H. The vaccination game. Risk Management and Decision Processes Center Working Paper No. 05-10-HK 2005, Risk Management and Decision Processes Center, Wharton School, University of Pennsylvania, Philadelphia.
57. Hershey J.C., Asch D.A., Thumasathit T., Meszaros J., Walters V. The roles of altruism, free riding, and bandwagoning in vaccination decisions. Org Behav Hum Dec Proc 1994, 59:177-187.
58. Newman P.A., Duan N., Rudy E., Roberts K., Swendeman D. Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV. J AIDS 2004, 37:1393-1403.
59. Ritvo P., Irvine J., Klar N., Wilson K., Brown L., Bremner K., et al. A Canadian national survey of attitudes and knowledge regarding preventive vaccines. J Immune Based Ther Vaccines 2003, 1:3.
60. Zimet G., Fortenberry J.D., Blythe M., Dairaghi J., Schering S. Health beliefs and vaccine characteristics predict HIV vaccine acceptance among adolescent patients. J Adolesc Health 1996, 18:148.
61. Hofmann F., Ferracin C., Marsh G., Dumas R. Influenza vaccination of healthcare workers: a literature review of attitudes and beliefs. Infection 2006, 34:142-147.
62. Basayau F., Josset V., Merle V., Czernichow P. Case fatality and health care costs in HIV-infected patients: Evolution from 1992 to 2000 at Rouen University Hospital, France. Int J STD AIDS 2004, 15:679-684.
63. Shackman B.R., Geboo K.A., Walensky R.P., Losina E., Muccio T., Sax P.E., et al. The lifetime cost of current Human Immunodeficiency Virus care in the United States. Med Care 2006, 44:990-997.